HomeCompareVPRO vs CL

VPRO vs CL: Dividend Comparison 2026

VPRO yields 10000000.00% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VPRO wins by $4.762052817831319e+46M in total portfolio value
10 years
VPRO
VPRO
● Live price
10000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.762052817831319e+46M
Annual income
$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00
Full VPRO calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — VPRO vs CL

📍 VPRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVPROCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VPRO + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VPRO pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VPRO
Annual income on $10K today (after 15% tax)
$850,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$40,476,652,714,542,950,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, VPRO beats the other by $40,476,652,714,542,950,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VPRO + CL for your $10,000?

VPRO: 50%CL: 50%
100% CL50/50100% VPRO
Portfolio after 10yr
$2.3810264089156593e+46M
Annual income
$23,809,795,714,437,028,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

VPRO
No analyst data
Altman Z
-0.9
Piotroski
2/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VPRO buys
0
CL buys
0
No recent congressional trades found for VPRO or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVPROCL
Forward yield10000000.00%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$4.762052817831319e+46M$40.8K
Annual income after 10y$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00$5,401.96
Total dividends collected$4.762046689458665e+46M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: VPRO vs CL ($10,000, DRIP)

YearVPRO PortfolioVPRO Income/yrCL PortfolioCL Income/yrGap
1← crossover$1,000,010,700$1,000,000,000.00$11,012$312.01+$1000.00MVPRO
2$93,460,013,936,683$93,458,943,925,233.62$12,196$412.95+$93460013.92MVPRO
3$8,163,259,573,940,183,000$8,163,159,571,725,270,000.00$13,599$549.66+$8163259573940.17MVPRO
4$666,373,880,559,373,300,000,000$666,365,145,871,629,100,000,000.00$15,288$736.64+$666373880559373312.00MVPRO
5$50,838,057,311,279,720,000,000,000,000$50,837,344,291,227,520,000,000,000,000.00$17,353$995.28+$5.083805731127972e+22MVPRO
6$3,624,737,622,195,432,400,000,000,000,000,000$3,624,683,225,474,109,500,000,000,000,000,000.00$19,926$1,357.80+$3.6247376221954326e+27MVPRO
7$241,535,451,261,763,920,000,000,000,000,000,000,000$241,531,572,792,508,160,000,000,000,000,000,000,000.00$23,194$1,873.82+$2.4153545126176394e+32MVPRO
8$15,041,872,435,857,020,000,000,000,000,000,000,000,000,000$15,041,613,992,924,168,000,000,000,000,000,000,000,000,000.00$27,439$2,621.52+$1.504187243585702e+37MVPRO
9$875,466,765,540,973,800,000,000,000,000,000,000,000,000,000,000$875,450,670,737,467,500,000,000,000,000,000,000,000,000,000,000.00$33,088$3,727.38+$8.754667655409739e+41MVPRO
10$47,620,528,178,313,184,000,000,000,000,000,000,000,000,000,000,000,000$47,619,591,428,874,056,000,000,000,000,000,000,000,000,000,000,000,000.00$40,806$5,401.96+$4.762052817831319e+46MVPRO

VPRO vs CL: Complete Analysis 2026

VPROStock

Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis. It manufactures biologics drugs, including bio-similars for pre-clinical, and Phase I, II, and III clinical trials; offers its clients with supply of mammalian cell proteins, such as monoclonal antibodies or recombinant proteins, or other cell-derived products; owns three clones that include two in insulin therapy and one for cancer therapy; and provides contractual research and manufacturing services to biotech and biopharmaceutical companies. The company's contractual work activities include cloning, sequencing, purifying, developing, validating, and producing biopharmaceutical products and sub-products. It has operations in Canada, the United Kingdom, and Malaysia. Viropro Inc. has collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products. The company is based in San Jose, California. Viropro Inc. is a subsidiary of Alpha Biologics Limited.

Full VPRO Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this VPRO vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VPRO vs SCHDVPRO vs JEPIVPRO vs OVPRO vs KOVPRO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.